An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.

The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD ...

HRH Prince Salman highlighted the Kingdom’s medical milestone in successfully completing the treatment of the world’s first sickle cell disease patient outside the US with Casgevy (exagamglogene ...

Bahrain has achieved a medical milestone by successfully treating a patient with sickle cell disease (SCD) using CRISPR-based gene-editing therapy, Casgevy, the Bahrain Oncology Center said on Sunday.

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

What’s the full story? Seaport lays out a bullish case, starting with the massive total addressable market for groceries, ...

His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, reaffirmed Bahrain’s commitment ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.